Deals
Catalent Rises on Report Lonza Group Offered to Buy It
This article is for subscribers only.
Catalent Inc., a company offering technologies that deliver drugs into targeted cells and tissues, surged after Reuters reported that Lonza Group AG offered to buy it.
No deal has been reached between the companies, and the negotiations may not continue, according to Reuters. Swiss-based Lonza supplies products such as stem cells to biotechnology and pharmaceutical companies.